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Abstract We have investigated the possible role of selected neg- 
atively-charged amino acids of the sodium and chloride-coupled 
GABA transporter GAT-I on sodium binding. These residues 
located adjacent to putative transmembrane domains and which 
are conserved throughout he large superfamily of neurotransmit- 
ter transporters were changed by site-directed mutagenesis. The 
functional consequences were that one of the residues, glutamat¢~ 
101, was critical for transport. Its replacement by aspartate left 
only 1% of the activity, and no activity could be detected when 
it was replaced by other residues. Expression levels and targeting 
to the plasma membrane of the mutant transporters appeared 
normal. Transient sodium currents were not observed in the mu- 
tants, and increased sodium concentrations did not affect the 
percentage of wild type transport of the E101D mutant. It is 
concluded that residue glutamate-101 is critical for one or more 
of the conformational changes of GAT-1 during its transport 
cycle. 
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1. Introduction 
Transporters which couple the flux of neurotransmitters to 
that of sodium are thought to play an important role in the 
termination of synaptic transmission (for a review see [1]). 
GAT-1 is a transporter for the neurotransmitter 7-aminobu- 
tyric acid (GABA) which was reconstituted and purified to near 
homogeneity [21. It was the first to be cloned [31 and serves as 
a prototype of a large superfamily of sodium- and chloride- 
dependent neurotransmitter transporters (see [4] and [5] for 
reviews). It catalyses the electrogenic cotransport of the neuro- 
transmitter molecule with one chloride and two or three sodium 
ions [6-8]. Using a site-directed mutagenesis approach we have 
attempted to identify amino acid residues of the transporter 
involved in sodium binding. We have changed charged amino 
acids located in the 12 putative transmembrane domains (TD) 
[9]. This revealed that only arginine-69 located in the first TD 
is critical. Based on evidence that aromatic amino acids, and 
especially tryptophans, may interact with positively charged 
substrates via their x-electrons [10], the tryptophan residues 
located in the putative TD's of the transporter were changed 
*Corresponding author. Fax: (972) (2) 757379. 
Abbreviations: GABA, 7-aminobutyric a id; TD: transmembrane do-
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[11]. One out of the two residues identified to be important for 
function tryptophan-222 is not conserved throughout the 
superfamily and therefore is unlikely to be involved in sodium 
binding. The other - tryptophan-68 - is conserved throughout 
and may play a role in sodium binding. However, as significant 
activity is observed for a mutant where this residue was re- 
placed with a serine (see [11] and Mager, S., unpublished exper- 
iments), it appears likely that other determinants are involved 
in the process. In this paper we have investigated the role of 
conserved negatively charged residues which are predicted to 
be located close to the putative TD's. Due to uncertainties in
the predictive ability of hydrophaty plots, such residues could 
well be located in the TD's. It appears that one of these residues 
- glutamate-101 - is essential for the function of the trans- 
porter. 
2. Materials and methods 
2.1. Mater&& 
Polynucleotide kinase, DNA-polymerase, and DNA-ligase (all from 
T4) were from Boehringer Mannheim. Restriction enzymes were from 
New England Biolabs and Boehringer Mannheim. Sequenase kits (ver- 
sion 2.0) were from U.S. Biochemical Corp. D-[35S]0~ATP (1,000 Ci] 
mmol) and [35S]methionine (1,000 Ci/mmol) were from Amersham 
Corp. [3H]GABA (47.6 Ci/mmol) was from the Nuclear Research Cen- 
ter, Negev, Israel. The tissue culture medium, serum, penicillin/strepto- 
mycin and L-glutamine were from Biological Industries, Kibbutz Bet 
Ha'Emek, Israel. Transfection reagent (DOTAP) was from Boehringer 
Mannheim. Brain lipids were prepared from bovine brain as published 
[12]. Protein A-Sepharose CL-4B, asolectin (P-5638, type II S), valino- 
mycin, uridine, cholic acid, and all other materials were obtained from 
Sigma. The antiserum against residues 571-586 of the GAT-1 trans- 
porter, IQPSEDIVRPENGPEQ (Pcoo., part of the carboxyl terminal) 
was prepared as described [13]. The PcooH peptide was a generous gift 
from Dr. Reinhard Jahn (Yale University Medical School, New Haven, 
CT). 
2.2. Site-directed mutagenesis 
Mutagenesis was performed as described [14]. The shortened GAT-I 
clone [9] was used to transform Escherichia coli CJ 236 to ampicillin 
resistance. From one of the transformants single-stranded uracil con- 
taining DNA was isolated upon growth in a uridine-containing medium 
according to the standard protocol from Stratagene, using helper phage 
R408. This yields the sense strand, and consequently the mutagenic 
primers were designed to be antisense. 
The following primers were used to make the following mutations 
(names in parenthesis; the altered antisense nucleotides are underlined): 
5'-GCC TAG GGA GCA CCC CAA AAG GAA GAG A-3' (E101G); 
5'-GCC TAG GGA GCA G(_G_.~_)TC AA AAG GAA GAG A-3' 
(E101D); 5'-CTA GGG AGC ACT GCA AAA GGA AGA GAG 
GAA-3' (E101Q); 5'-GCC TAG GGA GCA TGC CAA AAG GAA 
GAG A-3' (E101A); 5'-ATC TGG GTG GCG GCG CCA AGC CAC 
ACC TCA GAA T-3' (D287G); 5'-AGG ACA TGA (~GA AGC CGA 
AGC GTC CCT T-3' (D52G); 5'-AAC AAT GAT GGA GCC CCT 
GTA CAC ATT G-3' (D319G). 
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Mutations were confirmed by DNA sequencing and subcloned into 
wild type. For the mutations at position 101 and 52 the enzymes AvrII 
and XhoI were used. For the D287G mutation the enzymes PpuMI and 
NheI were used and for D319G we used PpuMI and BsmI. The sub- 
cloned DNAs were sequenced from both directions between the sites 
of the indicated restriction enzymes. 
2.3. Cell growth and expression 
HeLa cells were cultured in Dulbecco's modified Eagle's medium 
supplemented with 10% fetal calf serum, 200 units/ml penicillin, 200 
/lg/ml streptomycin, and 2 mM glutamine. Infection with recombinant 
vaccinia/T7 virus vTF7-3 and subsequent transfection with plasmid 
DNA, GABA transport and immunoprecipitation were done as pub- 
lished previously [15]. Protein was determined as described by Bradford 
[16]. SDS-polyacrylamide g l electrophoresis was as described by 
Laemmli [17] using a 4% stacking and 10% separating el. Size stand- 
ards (Pharmacia LKB Biotechnology Inc.) were run in parallel and 
visualized by Coomassie Blue staining. Reconstitution ftransport was 
done as follows: For each experiment infected/transfected c lls from 
two large wells (35-ram diameter) were used for each mutant. They were 
washed twice with 1 ml of phosphate-buffered saline and taken up in 
a small volume of phosphate-buffered saline using a rubber policeman. 
To 35/11 of this suspension were added (in this order) 15/11 of 0.1 M 
KPi (pH 7.5), and 10 ¢tl of 20% cholic acid (neutralized by NaOH). After 
10 min of incubation on ice, the mixture was reconstituted with 
asolectin/brain l pids using spin columns, and transport was measured 
exactly as described [18]. 
2.4. Electrophysiology 
Wild type and mutant GAT constructs were transferred to pAMV- 
PA [19] and cRNA was generated by Ambion's MEGAscript kit, using 
T7 RNA polymerase. Standard oocyte injection procedures were used. 
Recording solutions were as follows: standard medium, ND96, con- 
tained 96 mM NaC1, 2 mM KCI, 1 mM MgC12, 0.1 mM CdCI2 and 5 
mM HEPES (pH 7.4). The Li ÷ substitution for Na+ contained 96 mM 
LiC1, 2 mM KC1, 1 mM MgCI2, 0.1 mM CdCl 2 and 5 mM HEPES (pH 
7.4). Two-microelectrode voltage-clamp procedures were used. Steady 
state and transient currents were measured as described [8]. Data acqui- 
sition and analysis utilized the pCLAMP program suit (Axon Instru- 
ments, Foster City, CA). For measurements of GABA currents, the 
membrane potential was held at -80 mV unless noted otherwise. 
3. Results and discussion 
There are four negatively-charged amino acids in GAT-1 
which are conserved throughout he large superfamily of neu- 
rotransmitter t ansporters and are located adjacent o putative 
TD's. These are aspartate residues 52, 287 and 319 located on 
the amino terminal side of putative TD's I, VI and VII, respec- 
tively, and glutamate-101 located at the carboxyl terminal side 
of putative TD II. Each of these residues has been mutated to 
glycine. The cDNA's  carrying these mutants as well as the wild 
type were cut with the appropriate restriction enzymes (see 
section 2) so that a relatively small fragment of the mutant 
cDNAs could be subcloned into the wild type. These inserted 
fragments were sequenced in both directions and found to be 
unchanged with regard to the wild type, except for the mutation 
itself. The cDNAs of these subcloned mutants were expressed 
in HeLa cells using the recombinant vaccinia/T7 virus [20] as 
described [15]. Fig. 1 shows that D52G, D287G and D319G 
exhibit considerable sodium-dependent [3H]GABA transport. 
On the other hand there is no detectable activity in E101G. 
These results indicate that glutamate-101 may be important for 
the function of the GABA transporter GAT-1. In order to 
study the functional role of side chain structure at position 101, 
the wild type glutamate residue was mutated to several other 
amino acids. These mutations were subcloned and verified by 
sequencing as above. The results of expression experiments 
with the mutant cDNAs are summarized in Fig. 2. The results 
indicate that it is the glutamate residue itself which is important, 
as also the E101A and E101Q mutants do not exhibit significant 
transport activity. A small but consistent ransport activity 
around 1% of the wild type is observed with the E101D 
mutant. Thus, while it is clear that a negative charge at this 
position is important, this is not sufficient. Optimal transport 
is only observed when it is occupied by glutamate. 
The impaired transport of the mutants is not due to lower 
transporter levels. Wild type and mutant transporters were 
expressed in HeLa cells, labelled with [35S]methionine and im- 
munoprecipitated by an antibody raised against a peptide lo- 
cated in the carboxyl terminal of GAT-1 (Fig. 3). The trans- 
porter monomer uns as a 67 kDa polypeptide on SDS-poly- 
acrylamide gels [3,9,11,13] and the wild type is displayed in lane 
1. It is not expressed in HeLa cells transfected with the vector 
alone (lane 2). In contrast, all of the mutant clones in which 
glutamate-101 was replaced, express high transporter levels 
(Fig. 3, lanes 3-6). Although it appears that in this experiment 
the expression levels of the mutant transporters i higher than 
the wild type, in other experiments the level of wild type ap- 
peared similar to that of the mutants. 
Because the mutants till produce normal transporter levels, 
it is possible that they are inefficiently targeted to the plasma 
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Fig. 1. [3H]GABA uptake by the various mutant proteins. HeLa cells 
were infected with recombinant vaccinia/T7 virus and transfected with 
pBluescript containing wild type, the vector without he insert (SK) or 
the indicated mutants. Results are given as percent of sodium-depend- 
ent transport of the mutants relative to that of the wild type. Each bar 
is the mean + S.E.M. of six to eight different experiments. 
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Fig. 2. [3H]GABA uptake by the mutants in position 101. HeLa cells 
were infected with recombinant vaccinia/T7 virus and transfected with 
pBluescript containing wild type, the vector without he insert (SK) or 
the indicated mutants. Results are given as percent of sodium-depend- 
ent transport of the mutants relative to that of the wild type. Each bar 
is the mean _+ S.E.M. of seven to eight different experiments. 
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Fig. 3. Immunoprecipitation of wild type and non-active mutant GAT- 
1 proteins synthesized in HeLa cells. HeLa cells were infected with 
recombinant vaccinia/T7 virus and transfected with pBluescript con- 
taining wild type, the indicated mutants or the vector without insert. 
The cells were labelled with [35S]methionine, lysed and immunoprecipi- 
tated with anti PCOOH, as described under section 2.2. Lane 1, wild type; 
2, vector alone; 3, E101A; 4, 101G; 5, E101D; 6, E101Q. 
0 
0 
O 
to  
A k-- 
oo o 
v 
k-- 
n- 
O 
o a.  
Z 
n-" 
I--  
o < 
• m 
CO 
"1- 
o) 
0 
tO 
d 
~ o  o 
< 0 Q 0 d 
,T, ~ ,T, 
Fig. 4. [3H]GABA uptake in proteoliposomes containing mutant rans- 
porters or vector alone. HeLa cells were infected with recombinant 
vaccinia/T7 virus and transfected with pBluescript containing wild type, 
the indicated mutants or the vector without he insert (SK). The cells 
were treated with cholate, and solubilized proteins were reconstituted 
with asolectin/brain lipids using spin columns as described under sec- 
tion 2.2. The results are averages of three experiments; 1(~30/lg of 
protein were used per transport reaction. Bars (mean + S.E.M.) repre- 
sent net values of transport in 150 mM NaCI. 
membrane. One would expect that cells expressing a mutant 
transporter that is intrinsically active would have a cryptic 
transport activity. Detergent extraction of the cells expressing 
such a transporter followed by reconstitution of the solubilized 
proteins is likely to yield transport activity even if they were 
originally residing in internal membranes. In fact, such cryptic 
transport activity has been observed using this assay with some 
mutants of GAT-1 [11] and of the glutamate transporter GLT-1 
[21]. In this series of experiments he glutamate transport in the 
wild type ranges from 6-10 pmol/min/mg protein. This is simi- 
lar to the values observed in whole cells. This activity is com- 
pletely sodium-dependent and is not observed with cells ex- 
pressing the vector alone (Fig. 4). 
The E101A, E101G and E101Q mutants which do not exhibit 
detectable transport activity in whole cells, also remain com- 
pletely void of activity after solubilization and reconstitution 
(Fig. 4). The small but consistent activity of the E 101D mutant 
is only slightly enhanced under these conditions (Figs. 2 and 4). 
In view of these results, it appears highly unlikely that defective 
targeting is the cause of the impaired GABA transport of mu- 
tants at the glutamate-101 position. 
The activity of the E101D transporter is too low to analyze 
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Fig. 5. GABA-induced currents for normal or mutant ransporters 
expressed inXenopus oocytes. GABA-induced currents were measured 
in standard perfusion medium. Oocytes were injected with cRNA for 
(A) wild type, (B) E101D, or (C) E101Q. Note the increased amplifica- 
tion for traces in (B) and (C). 
for systematic dose-response studies with [3H]GABA flux. 
Therefore, transport was measured by electrophysiological 
methods, utilizing the observation that transport iselectrogenic 
[8]. It can be observed that even at 1 mM GABA, a concentra- 
tion 2 orders of magnitude larger than its Km for the trans- 
porter, the sodium-dependent transport current of the E101Q 
transporter is undetectable - similar to those of E101G and 
E101A (data not shown). The transport current of the E101D 
mutant is about 1% of that of the wild type (Fig. 5). As this is 
similar to the results obtained with tracer flux experiments (Fig. 
2) in which the GABA concentration was 42 nM, it is obvious 
that it is not the affinity for GABA which is affected in the 
mutant. As transporter levels of El01D are not decreased (Fig. 
3) and a targeting problem does not appear to underlie the 
defect, the results are consistent with a defect of sodium binding 
in this mutant. Furthermore, the transient sodium binding cur- 
rent observed with the wild type [8] is not observed in the 
E101D mutant (data not shown), but it should be mentioned 
that only transients of at least 10% of the wild type could have 
been detected. This transient is thought to reflect sodium bind- 
ing to the transporter followed by some charge redistribution, 
but is independent of GABA binding [8]. Therefore, this result 
is consistent with the idea that a defect in the binding or debind- 
ing of sodium is caused by the E 101D mutation. We have tested 
this idea using the reconstituted system to increase xternal 
sodium and chloride 4-fold to 0.6 M, and simultaneously b
elevating the internal potassium phosphate by the same factor. 
The percentage of transport by the E101D mutant was not 
increased under these conditions (data not shown). This result 
indicates that a lowered affinity to either of these two ions is 
not likely to underlie the defective transport of the El01 muta- 
tion. Our results are best explained by either of the following 
two scenarios. 
One is that glutamate-101 is required for the execution of the 
conformational change of the transporter induced upon so- 
dium binding, e.g. the above-mentioned charge distribution. 
Alternatively, the residue could fulfill a critical role in the ability 
of the unloaded transporter to undergo a conformational 
change, such that the mutant ransporter would be locked in 
the inward facing conformation. Future biochemical studies on 
the various conformational changes - along the lines of those 
already initiated [22] - may help to distinguish between these 
possibilities. 
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